Therapy of peritoneal carcinomatosis of human colon cancer xenografts with yttrium 90-labeled anti-carcinoembryonic antigen antibody ZCE025
D. M. Hyams, J. M. Esteban, C. P. Lollo, B. G. Beatty and J. D. Beatty
Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, CA 91010.
The present study was undertaken to determine whether an
anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAB), labeled with
the potent beta emitter yttrium 90, could alter the growth of diffuse
intraperitoneal carcinomatosis of colon cancer. Nude mice bearing the
CEA-producing human tumor line LS174T received therapy with the anti-CEA
MAB ZCE025 90Y. Animals were evaluated 12 days after therapy. Untreated
animals had a mean (+/- SEM) tumor burden of 3.99 +/- 0.10 g, while animals
treated with ZCE025 90Y had 0.29 +/- 0.04 g present. This decrease was
significant compared with the 1.31 +/- 0.16 g of tumor present in animals
treated with a 90Y-labeled nonspecific antibody 96.5c. The therapeutic
effects seen with ZCE025 90Y suggest a potentially useful role for
90Y-labeled anti-CEA MABs in the treatment of gastrointestinal
carcinomatosis.
